{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT04410796","nct_id":"NCT04410796","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04410796. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"All patients will receive osimertinib 80mg orally daily. Subjects randomized to Arm A may be dispensed osimertinib for 2 cycles from Cycle 4 onward. Patients will be required to complete a pill diary beginning at Cycle 4.","label":"Osimertinib alone","type":"EXPERIMENTAL"},{"description":"All patients will receive osimertinib 80mg orally daily. Patients receive Carboplatin (AUC 5 IV q 3 weeks) and Pemetrexed (500mg/m2 IV q 3 weeks) for a total of 4 cycles followed by pemetrexed maintenance from cycle 8 onwards. Patients will be required to complete a pill diary beginning at Cycle 4.","label":"Osimertinib plus Carboplatin and Pemetrexed","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","Guardant Health, Inc."],"completion_date":{"date":"2027-05","type":"ESTIMATED"},"conditions":["Metastatic Non-small Cell Lung Cancer"],"enrollment":{"count":571,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-11","lead_sponsor":"Memorial Sloan Kettering Cancer Center","official_title":"A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2027-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Determine the progression-free survival","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2020-05-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","url":"https://clinicaltrials.gov/study/NCT04410796"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04410796"}